SCHEMBL17787458

SCHEMBL17787458

Cc1cccc(C)c1OC(=O)NC(Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)C(C(C)C)N1CCCNC1=O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.81
ABCC3 O15438 2/20 0.81
ABCC4 O15439 2/20 0.81
ABCB11 O95342 2/20 0.81
PGR P06401 2/20 0.81
ABCB1 P08183 2/20 0.81
ADORA3 P0DMS8 2/20 0.81
CHRM1 P11229 2/20 0.81
TBXA2R P21731 2/20 0.81
ADRA1A P35348 2/20 0.81
OPRM1 P35372 2/20 0.81
HTR2B P41595 2/20 0.81
SCN5A Q14524 2/20 0.81
ABCG2 Q9UNQ0 2/20 0.81
KCNH2 Q12809 1/20 0.81
CA2 P00918 1/20 0.40
CTSD P07339 2/20 0.39
GHSR Q92847 2/20 0.35
REN P00797 6/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17787455 1.00 CYP3A4 (0.81) CYP3A4ABCC3ABCC4ABCB11PGR
SCHEMBL20099131 1.00 CYP3A4 (0.81) CYP3A4ABCC3ABCC4ABCB11PGR
SCHEMBL20099154 0.94 CYP3A4 (0.72) CYP3A4ABCC3ABCC4ABCB11PGR
SCHEMBL20099153 0.94 CYP3A4 (0.72) CYP3A4ABCC3ABCC4ABCB11PGR
Lopinavir SCHEMBL3042268 0.89 CYP3A4 (1.00) CYP3A4ABCC3ABCC4ABCB11PGR
Lopinavir SCHEMBL22241592 0.89 CYP3A4 (1.00) CYP3A4ABCC3ABCC4ABCB11PGR
Lopinavir SCHEMBL13065521 0.89 CYP3A4 (1.00) CYP3A4ABCC3ABCC4ABCB11PGR
Lopinavir SCHEMBL22382744 0.89 CYP3A4 (1.00) CYP3A4ABCC3ABCC4ABCB11PGR
Lopinavir SCHEMBL13370718 0.89 CYP3A4 (1.00) CYP3A4ABCC3ABCC4ABCB11PGR
Lopinavir SCHEMBL21775 0.89 CYP3A4 (1.00) CYP3A4ABCC3ABCC4ABCB11PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9352010-B2 Treatment of HIV-1 infection and AIDS THE J. DAVID GLADSTONE INSTITUTES (US) 2016-05-31 US disclosed